Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Canadian Government investments as they relate to the biopharmaceutical industry.
Justine Frame · Policy Advisor, Health Canada (HC)
Free trade agreements as they relate to the biopharmaceutical industry.Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Canadian Government investments as they relate to the biopharmaceutical industry.
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Vaccine Funding - National Immunization Strategy - maintain federal leadership in providing provinces with funding for new vaccinesRead more
VACCINE CONTRACTING AND SUPPLY to support the implementation of the federal biomanufacturing strategy, regulation of vaccines for Canadians, address immunization gaps, provide updated and timely information about vaccine development pipeline, support procurement of vaccines
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologies
Canadian Government investments as they relate to the biopharmaceutical industry.
Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Shalene Curtis-Micallef · Deputy Minister of Health, Health Canada (HC)
PATENTED MEDECINES PRICES REVIEW BOARD (PMPRB) PRICE REVIEW to ensure new guidelines and directives do not create disincentives for the introduction of new treatments in CanadaRead more
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
CANADIAN ENVIRONMENTAL PROTECTION ACT AND REGULATIONS in respect of modern, science-based regulations to reflect rapidly changing new technologiesRead more
ORPHAN PRODUCTS to establish formal regulations, policies or programs to encourage the research, development and introduction of new technologies to treat "orphan" or neglected diseases
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)
FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologies
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)Read more
FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologies
ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertainty
Ritu Banarjee · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologiesRead more
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)
ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertainty
David Lee · Chief Regulatory Officer, Health Canada (HC)
FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologiesRead more
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)
Ritu Banarjee · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologiesRead more
INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)
ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertainty
Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banarjee · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
SUBMISSION REVIEW PROCESS FOR BIOLOGICS, COST RECOVERY REVIEW to ensure Canada remains competitive overall and any new costs do not put bioloigics are a comparative disadvantageRead more
RESEARCH & DEVELOPMENT (R&D) to ensure Canadian capacity in key sectors including biomanufacturing, life sciences, and biotechnology.
Sandenga Yeba · Senior Policy Advisor, Deputy Director of Policy, Health Canada (HC)
ACCESS & BENEFIT SHARING: TRIPS AGREEMENT in respect of protecting intellectual property and preventing increased uncertaintyRead more
FOOD AND DRUGS ACT AND REGULATIONS in respect of streamlining regulatory burden and ensuring appropriate climate for the introduction of new technologies
David Lee · Chief Regulatory Officer, Health Canada (HC)
SUBMISSION REVIEW PROCESS FOR BIOLOGICS, COST RECOVERY REVIEW to ensure Canada remains competitive overall and any new costs do not put bioloigics are a comparative disadvantageRead more
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.